Published in Br J Haematol on February 01, 1973
Experimental hypercalcaemia and whole blood clotting. J Clin Pathol (1973) 1.10
Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host. Br J Cancer (1981) 0.75
Transluminal endoscopic necrosectomy after acute pancreatitis: a multicentre study with long-term follow-up (the GEPARD Study). Gut (2009) 5.08
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy (2005) 2.49
[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81
Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med (1993) 1.80
The structure of cat muscle pyruvate kinase. EMBO J (1986) 1.74
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
[S3-guideline colorectal cancer version 1.0]. Z Gastroenterol (2013) 1.51
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol (2001) 1.34
Prostacyclin deficiency in thrombotic thrombocytopenic purpura. Lancet (1979) 1.27
Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer (1977) 1.26
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol (2010) 1.16
The effect of heparin on the initial phase of metastasis formation. Eur J Cancer (1972) 1.15
An improved TnMax mini-transposon system suitable for sequencing, shuttle mutagenesis and gene fusions. Gene (1995) 1.15
Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology (1995) 1.14
Experimental hypercalcaemia and whole blood clotting. J Clin Pathol (1973) 1.10
Sequence of Escherichia coli D-serine dehydratase. Location of the pyridoxal-phosphate binding site. FEBS Lett (1981) 1.06
Divergent hemodynamic and hormonal responses to varying salt intake in normotensive subjects. Hypertension (1993) 1.03
Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br J Cancer (1977) 1.01
Ifosfamide--current aspects and perspectives. Cancer Treat Rev (1983) 1.01
Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol (2005) 1.00
Ischaemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastroenterology (1987) 1.00
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol (1989) 0.99
A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett (1997) 0.95
The role of blood platelets in experimental metastases. Br J Cancer (1973) 0.95
Microangiopathic haemolytic anaemia and experimental tumour-cell emboli. Br J Haematol (1974) 0.94
Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol (1998) 0.94
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res (1992) 0.93
D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol (1995) 0.93
The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1976) 0.92
25-hydroxy-vitamin-D in nephrotic syndrome. Lancet (1977) 0.92
[Immunological and electrophoretic characterization of flagellins of different H-types of Pseudomonas aeruginosa (author's transl)]. Med Microbiol Immunol (1980) 0.92
Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol (1984) 0.92
Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem (1998) 0.91
Anticoagulants in the treatment of cancer. Eur J Cancer (1976) 0.90
Acute hypercalcemia due to Walker carcinosarcoma 256 in the rat. Horm Metab Res (1970) 0.89
Aspirin and tumour metastasis. Lancet (1972) 0.89
Platelet shape change abnormalities in diabetic retinopathy. Diabetologia (1980) 0.88
Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo (2010) 0.87
Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat (1992) 0.87
Factor X-activating activity from Lewis lung carcinoma. Br J Cancer (1980) 0.87
A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7. J Biol Chem (2000) 0.87
Investigation of infectious organisms causing pericoronitis of the mandibular third molar. J Oral Maxillofac Surg (2000) 0.87
[Blue rubber-bleb nevus syndrome and therapeutic double balloon enteroscopy]. Z Gastroenterol (2006) 0.86
[Intravascular coagulation in solid Walker carcinosarcoma 256]. Schweiz Med Wochenschr (1971) 0.84
[Antibody response to somatic and flagellar antigens of Pseudomonas aeruginosa (author's transl)]. Med Microbiol Immunol (1978) 0.84
[Hypercalcemic activity of Walker carcinosarcoma 256 in the rat]. Schweiz Med Wochenschr (1971) 0.84
Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene (1996) 0.84
Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Eur J Cancer (1979) 0.84
Ultrasonography of achilles tendons in primary hypercholesterolemia. Comparison with computed tomography. Atherosclerosis (1988) 0.83
Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer (1995) 0.83
Observer-independent registration of perspective projection prior to subtraction of in vivo radiographs. Dentomaxillofac Radiol (1998) 0.82
Polymorphisms in the tumor necrosis factor genes in Wegener's granulomatosis. Exp Clin Immunogenet (1997) 0.82
Colonic haemorrhage from solitary submucosal vessels diagnosed by lower gastrointestinal Doppler-endoscopy. Endoscopy (1987) 0.82
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat Rev (1990) 0.82
Histometric investigations on the testicular tissue of rats with alloxan diabetes and Chinese hamsters with spontaneous diabetes. Acta Endocrinol (Copenh) (1967) 0.81
[Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification]. Pathologe (2011) 0.81
The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung (1989) 0.80
[Multicenter prospective study of the current status of treatment for bleeding ulcer in Germany]. Dtsch Med Wochenschr (1995) 0.80
[Changes in human heart valves due to aging]. Med Welt (1967) 0.80
Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines. Eur J Cancer (1994) 0.80
Thrombin-induced disseminated intravascular coagulation. III:Modification by dextran infusion. Br J Anaesth (1975) 0.79
Synthesis of procoagulant antihaemophilic factor in vitro. Lancet (1979) 0.79
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol (1981) 0.79
[Not Available]. Ber Wiss (1983) 0.79
[Thermic studies during drilling in compact bone with different cooling systems]. Dtsch Zahnarztl Z (1988) 0.79
Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol (1992) 0.79
Etoposide--chemistry, preclinical and clinical pharmacology. Cancer Treat Rev (1982) 0.78
[Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates (author's transl)]. Dtsch Med Wochenschr (1977) 0.78
Current development of podophyllotoxins. Cancer Chemother Pharmacol (1982) 0.78
Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol (1984) 0.78
Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives. Cancer Treat Rev (1985) 0.78
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur J Cancer (1993) 0.78
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie (1988) 0.78
Effectiveness of a novel endoscopy training concept. Endoscopy (2011) 0.78
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol (2011) 0.78
The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide. Invest New Drugs (1984) 0.77
[Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]. Rofo (2010) 0.77
Studies of human serum amyloid P-component (SAP) in relation to coagulation. Clin Chim Acta (1980) 0.77
Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. Biochim Biophys Acta (1990) 0.77
[The cytotoxic effect of plasmin on yoshida sarcoma cells]. Z Krebsforsch (1969) 0.77
Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin. Eur J Biochem (1995) 0.77
Basis and new developments in the field of oxazaphosphorines. Cancer Invest (1988) 0.77
A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. Thromb Haemost (1984) 0.77
The antioxidant LY 231617 ameliorates functional and morphological sequelae induced by global ischemia in rats. Brain Res (1995) 0.77
The appearance of schistocytes in the peripheral blood in correlation to the degree of disseminated intravascular coagulation. An experimental study in rats. Haemostasis (1976) 0.77
Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone. Eur J Cancer (1996) 0.77
D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol (1990) 0.77
The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation. Cancer Chemother Pharmacol (1993) 0.77
Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost (1986) 0.77
Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models. Cancer Immunol Immunother (1989) 0.77
Highly sensitive northern hybridization of rare mRNA using a positively charged nylon membrane. Biotechniques (1994) 0.77
[Fibrinogen elevation in malignant tumors--an unspecific symptom]. Verh Dtsch Ges Inn Med (1969) 0.77
[The diagnostic and therapeutic function of initial interviews in a psychotherapy clinic]. Psyche (Stuttg) (1981) 0.77
Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry (1999) 0.76